• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine

    2/24/22 8:30:00 AM ET
    $BDSI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BDSI alert in real time by email

    The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults

    Expands BDSI Portfolio and Establishes Growth Platform in Neurology

    RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults.

    "ELYXYB represents a significant innovation in the rapidly growing migraine market and our initial entry into the Neurology space, which is complementary to our current sales and marketing efforts," stated Jeff Bailey, CEO of BDSI. "We have been diligently preparing for this launch and are ready and excited to deliver this important acute treatment option to patients who are experiencing the life-altering effects of migraine disease."

    Migraine is a debilitating condition for almost 40 million people in the U.S. Many patients with migraine are searching for acute treatments that provide relief quickly and conveniently, without interfering with daily quality of life.

    "Millions of patients are cycling through the multitude of current migraine treatments, searching for what will work quickly and what will last, whenever a migraine strikes," stated Peter McAllister, MD, Director of the New England Center for Neurology and Headache. "Physicians are looking for new treatment options that are effective, with favorable safety and tolerability, and less contraindications. ELYXYB is uniquely formulated to provide fast-acting, long-lasting relief in a convenient, ready-to-use oral solution, and will be a go-to option for many of my patients with migraine."

    ELYXYB is an oral solution of celecoxib, formulated using a self-microemulsifying drug delivery system (SMEDDS) that improves solubility and bioavailability leading to better absorption1. This allows for the administration of a lower dose of drug to achieve therapeutic effect relative to a higher dose of the conventional oral capsule, which doesn't have the rapid onset of action that migraine patients need. ELYXYB comes in a small, single-dose bottle that does not require premixing, shaking, or measuring, making it convenient for patients to take immediately upon the onset of a migraine attack.

    BDSI is committed to ensuring access to appropriate patients who are prescribed ELYXYB. The ELYXYB Passport Program provides access support and resources to both healthcare providers and patients, including a co-pay savings program.

    For more information on ELYXYB and the ELYXYB Passport Program visit ELYXYB.com.

    ELYXYB is protected by six Orange Book-listed method-of-use patents that expire in 2036 as well as by New Product Exclusivity expiring in May 2023.

    Please see Important Safety Information about ELYXYB below.

    ABOUT BIODELIVERY SCIENCES INTERNATIONAL, INC.

    BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of differentiated products that address serious and debilitating conditions, including chronic pain, migraine, and opioid-induced constipation.

    CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

    This press release and any statements of employees, representatives, and partners of BioDelivery Sciences International, Inc. ("BDSI") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to BDSI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of BDSI's management and are subject to significant risks and uncertainties, including those detailed in BDSI's filings with the Securities and Exchange Commission. Actual results including, without limitation, expectations regarding the commercial launch of ELYXYB and BDSI's expansion in to the neurology space, may differ materially from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond BDSI's control) including the risk that the current COVID-19 pandemic impacts on our supply chain, commercial partners, patients and their physicians and the healthcare facilities in which they work, and our personnel are greater than we anticipate, as well as those set forth in our 2020 annual report on Form 10-K filed with the US Securities and Exchange Commission and subsequent filings. BDSI undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

    ELYXYB INDICATION AND USAGE

    ELYXYB is indicated in adults for the acute treatment of migraine with or without aura.

    Limitations of Use: ELYXYB is not indicated for the preventive treatment of migraine.

    ELYXYB IMPORTANT SAFETY INFORMATION

    WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

    Cardiovascular Thrombotic Events



    • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use [see Warnings and Precautions (5.1)].
    • ELYXYB is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) and Warnings and Precautions (5.1)].
    Gastrointestinal Bleeding, Ulceration, and Perforation
    • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious (GI) events [see Warnings and Precautions (5.2)].

    ELYXB is contraindicated in patients with:

    • Known hypersensitivity to celecoxib, any components of the drug product, or sulfonamides (4)
    • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs (4)
    • In the setting of CABG surgery (4)

    To minimize the potential risk for an adverse cardiovascular (CV) event in NSAID-treated patients, use ELYXYB for the fewest number of days per month as needed, based on individual treatment goals. Physicians and patients should remain alert for the development of such events, throughout the entire treatment course, even in the absence of previous CV symptoms. Patients should be informed about the symptoms of serious CV events and the steps to take if they occur.

    Avoid the use of ELYXYB in patients with a recent myocardial infarction (MI) unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If ELYXYB is used in patients with a recent MI, monitor patients for signs of cardiac ischemia.

    NSAIDs, including ELYXYB, can cause serious gastrointestinal (GI) adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with celecoxib. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI ulcers, gross bleeding, or perforation caused by NSAIDs occurred in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. However, even short-term NSAID therapy is not without risk.

    Avoid the use of ELYXYB in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If ELYXYB is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

    Elevations of ALT or AST (less than three times ULN) may occur in up to 15% of patients treated with NSAIDs, including ELYXYB.

    Long-term administration of NSAIDs, including celecoxib, the active ingredient in ELYXYB, has resulted in renal papillary necrosis and other renal injury.

    No information is available from controlled clinical studies regarding the use of celecoxib in patients with severe renal impairment. The renal effects of celecoxib may hasten the progression of renal dysfunction in patients with preexisting renal disease.

    Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, nonsteroidal anti-inflammatory drugs or combination of these drugs for 10 or more days per month), including ELYXYB, may lead to exacerbation of headache (medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients, including withdrawal of the overused drugs and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.

    NSAIDs, including ELYXYB, may increase the risk of bleeding events. Co-morbid conditions such as coagulation disorders or concomitant use of warfarin, other anticoagulants, antiplatelet drugs (e.g., aspirin), SSRIs, and serotonin norepinephrine reuptake inhibitors (SNRIs) may increase this risk.

    Most common adverse reaction (at least 3% and greater than placebo) is dysgeusia.

    These are not all the side effects associated with ELYXYB.

    Please see Patient Information, Instructions For Use, Medication Guide and Full Prescribing Information for ELYXYB

    (https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212157s000lbl.pdf)

    1 Arindam Pal, Srinivas Shenoy, Anirudh Gautam, Sagar Munjal, Jing Niu, Mathangi Gopalakrishnan & Joga Gobburru, Clinical Drug Investigation volume 37, pages 937–946(2017)

    © 2022 BioDelivery Sciences International, Inc. All rights reserved.

    Contact:

    Bob Yedid

    LifeSci Advisors

    646-597-6989

    [email protected]



    Primary Logo

    Get the next $BDSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDSI

    DatePrice TargetRatingAnalyst
    2/15/2022$5.00 → $5.60Overweight → Neutral
    Piper Sandler
    1/21/2022$4.00 → $4.50Neutral
    HC Wainwright & Co.
    11/4/2021$6.00 → $4.50Buy → Neutral
    HC Wainwright & Co.
    8/5/2021$5.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BDSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genenta Provides First Half 2022 Business Update and Financial Results

      Current dose escalation study data shows a median overall survival of 17 monthsAdding cohort to Phase 1/2a trial in GBM to assess additional conditioning regimenCash and cash equivalents of €34.7 million as of June 30, 2022, providing a cash runway until the end of 2024€1.8 million unrealized foreign exchange gain MILAN, Italy and NEW YORK, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), ("Genenta" or the "Company"), a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, provides business and financial results for the six months ended June 30, 2022.

      10/24/22 7:30:00 AM ET
      $GNTA
      $BDSI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Genenta Announces Nomination of Mark A. Sirgo as Chair

      35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ:GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair. Stephen Squinto, PhD is stepping down from his role as Chair on May 1, 2022 to pursue a new business opportunity. Dr. Sirgo most recently was CEO of Aruna Bio, Inc., a preclinical biotech compan

      4/27/22 7:30:00 AM ET
      $BDSI
      $GNTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Collegium Completes the Acquisition of BDSI

      STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio

      3/22/22 5:01:00 PM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Leadership Updates

    Live Leadership Updates

    See more

    $BDSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer

      RALEIGH, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial Officer, effective November 4, 2021.  Mr. Golubieski brings to BDSI more than 30 years of financial and operational experience and will serve as a member of the company's executive leadership team. "I'm pleased to welcome John to our executive leadership team. His appointment comes at a time of significant opportunity and growth for BDSI," said Jeff Bailey, Chief Executive Officer. "I know first-h

      10/21/21 8:00:00 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

      BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an

      8/16/21 8:00:00 AM ET
      $AZRX
      $BCPC
      $BDSI
      Major Pharmaceuticals
      Health Care
      Major Chemicals
      Industrials
    • SEC Form 4: Watson W. Mark disposed of 90,663 shares, closing all direct ownership in the company to satisfy tax liability

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:18:46 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Vollins James (withholding tax)

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:18:09 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Singh Vanila disposed of 35,851 shares, closing all direct ownership in the company to satisfy withholding tax

      4 - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Issuer)

      3/22/22 5:17:22 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by BioDelivery Sciences International Inc. (Amendment)

      SC 13G/A - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/10/23 4:14:56 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by BioDelivery Sciences International Inc.

      SC 13D - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/24/22 12:05:58 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BioDelivery Sciences International Inc.

      SC 13G - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Subject)

      2/24/22 11:06:16 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BioDelivery Sciences Intl downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded BioDelivery Sciences Intl from Overweight to Neutral and set a new price target of $5.60 from $5.00 previously

      2/15/22 4:35:51 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on BioDelivery Sciences Intl with a new price target

      HC Wainwright & Co. reiterated coverage of BioDelivery Sciences Intl with a rating of Neutral and set a new price target of $4.50 from $4.00 previously

      1/21/22 6:26:41 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioDelivery Sciences Intl downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded BioDelivery Sciences Intl from Buy to Neutral and set a new price target of $4.50 from $6.00 previously

      11/4/21 7:12:11 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    Financials

    Live finance-specific insights

    See more
    • Collegium Completes the Acquisition of BDSI

      STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) ("Collegium") today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (NASDAQ:BDSI) ("BDSI"). "This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions," said Joe Ciaffoni, President and Chief Executive Officer of Collegium. "We have significantly diversified the business and expanded our overall revenue scale. This transaction is immediately and highly accretive, and we are now focused on seamless integratio

      3/22/22 5:01:00 PM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Collegium to Acquire BioDelivery Sciences Broadening Pain Portfolio

      - Expected to be Immediately and Highly Accretive Driven by Identified Annual Synergies of at Least $75 Million - - Will Diversify Revenue Growth and Accelerate Cash Flow Generation - - Addition of BELBUCA® Provides a Second Growth Driver and ELYXYB™ Establishes Foothold in Neurology - - Conference Call Scheduled for Today at 8:30 a.m. ET - STOUGHTON, Mass. and RALEIGH, N.C., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL) and BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced a definitive agreement pursuant to which Collegium will acquire BDSI for $5.60 per share in cash. BDSI has a portfolio of pain and neurology products that addre

      2/14/22 6:30:00 AM ET
      $BDSI
      $COLL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioDelivery Sciences Reports Solid Third Quarter 2021 Results

      Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential long-term peak sales opportunity of $350 - $400 million Conference Call and Webcast Scheduled for 8:30 AM EST Today RALEIGH, N.C., Nov. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported solid financial results for the third quarter ended

      11/3/21 8:00:00 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BDSI
    SEC Filings

    See more
    • SEC Form 15-12B filed by BioDelivery Sciences International Inc.

      15-12B - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      4/1/22 5:02:37 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by BioDelivery Sciences International Inc.

      EFFECT - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      3/28/22 12:15:08 AM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by BioDelivery Sciences International Inc.

      S-8 POS - BIODELIVERY SCIENCES INTERNATIONAL INC (0001103021) (Filer)

      3/23/22 5:30:38 PM ET
      $BDSI
      Biotechnology: Pharmaceutical Preparations
      Health Care